Celebrex has faced significant prescription reduction while its generics are not popular in the market, either

Celebrex, the Pfizer’s COX-2 type anti-inflammatory drug, has encountered significant decreases in prescriptions due to entry of its generics. Celebrex, whose patent was expired on the 11^th last June, has faced generic drugs since the 12^th and now decreased in price as well.

In other words, the price of Celebrex Cap 200mg has decreased 30% from KRW 973 to KRW 681. The price decrease of the dru...